Suven Life Sciences Limited — Updates, 16-07-2025: Press Release

Suven Life Sciences has initiated its pivotal Phase-2b clinical trial for Ropanicant (SUVN-911), with the first patient randomized. This novel α4β2 antagonist, targeting Major Depressive Disorder (MDD), builds on positive Phase-2a results demonstrating favorable safety and rapid onset. The study, enrolling approximately 195 patients across 35 US sites, aims to deliver a differentiated treatment with improved side effects. Topline data is anticipated in the second half of 2026, marking a key milestone in addressing significant unmet needs for MDD patients.